{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:42:30Z","timestamp":1710376950693},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:p>&lt;sec id=\"st1\"&gt;&lt;title&gt;BACKGROUND&lt;\/title&gt;Following the WHO\u2019s announcement in 2018, the use of new drugs was recommended for all patients with multidrug-resistant TB (MDR-TB) in Korea. This study aimed to evaluate adherence to new anti-TB drug regimens and implementation\n of molecular drug susceptibility testing (mDST) in Korea.&lt;\/sec&gt;&lt;sec id=\"st2\"&gt;&lt;title&gt;METHODS&lt;\/title&gt;Nationwide, 560 patients were reported as having MDR-TB in 2021. The implementation of mDST and new anti-TB drug use were analysed. The discrepancy between mDST\n and phenotypic DST (pDST) results and their implications on the use of new anti-TB drugs were also analysed. The use of novel anti-TB drugs has been approved by the National TB Expert Committee.&lt;\/sec&gt;&lt;sec id=\"st3\"&gt;&lt;title&gt;RESULTS&lt;\/title&gt;The non-adherence rate\n in MDR-TB patients was 14.3%. The mDST implementation rate was 96.1%. Of the 459 patients who underwent both mDST and pDST, the discordance rate for rifampicin (RIF) resistance was 22.6% (<jats:italic>n<\/jats:italic> = 104), of which 72.1% (<jats:italic>n<\/jats:italic> = 75) were resistant on mDST but susceptible on pDST. The discrepancy\n in mDST and pDST results related to RIF resistance was found to be the main cause of non-adherence to new drug regimen.&lt;\/sec&gt;&lt;sec id=\"st4\"&gt;&lt;title&gt;CONCLUSION&lt;\/title&gt;Comprehensive training on how to interpret conflicting results between mDST and pDST could enhance\n the utilisation of new drugs in the treatment of MDR\/RIF-resistant TB.&lt;\/sec&gt;<\/jats:p>","DOI":"10.5588\/ijtld.23.0237","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T04:33:21Z","timestamp":1706848401000},"page":"86-92","source":"Crossref","is-referenced-by-count":0,"title":["Compliance with new drug use and the effect of discrepant drug susceptibility testing on MDR\/RR-TB treatment"],"prefix":"10.5588","volume":"28","author":[{"given":"J. E.","family":"Shin","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Jeon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mok","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pusan National University Hospital, Busan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-J.","family":"Yim","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-S.","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Hospital, Gwangju,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K-W.","family":"Jo","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul, Division of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. S.","family":"Shim","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul, Division of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2024\/00000028\/00000002\/art00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T04:33:57Z","timestamp":1710304437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.23.0237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"alternative-id":["1027-3719(20240201)28:2L.86;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.23.0237","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}